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Background: With no cure for dementia and the number of people living with the condition 
predicted to rapidly rise, there is an urgent need for dementia risk reduction and prevention 
interventions. Modifiable lifestyle risk factors have been identified as playing a major role in the 
development of dementia; hence, interventions addressing these risk factors represent a signifi-
cant opportunity to reduce the number of people developing dementia. Relatively few interven-
tions have been trialed in older participants with cognitive decline (secondary prevention).
Objectives: This study evaluates the efficacy and feasibility of a multidomain lifestyle risk 
reduction intervention for people with subjective cognitive decline (SCD) and mild cognitive 
impairment (MCI).
Methods: This study is an 8-week, two-arm, single-blind, randomized controlled trial (RCT) of 
a lifestyle modification program to reduce dementia risk. The active control group receives the 
following four online educational modules: dementia literacy and lifestyle risk, Mediterranean 
diet (MeDi), cognitive engagement and physical activity. The intervention group also completes 
the same educational modules but receives additional practical components including sessions 
with a dietitian, online brain training and sessions with an exercise physiologist to assist with 
lifestyle modification.
Results: Primary outcome measures are cognition (The Alzheimer’s Disease Assessment 
Scale-Cognitive-Plus [ADAS-Cog-Plus]) and a composite lifestyle risk factor score for 
Alzheimer’s disease (Australian National University – Alzheimer’s Disease Risk Index 
[ANU-ADRI]). Secondary outcome measures are motivation to change lifestyle (Motivation 
to Change Lifestyle and Health Behaviour for Dementia Risk Reduction [MCLHB-DRR]) and 
health-related quality of life (36-item Short Form Health Survey [SF-36]). Feasibility will be 
determined through adherence to diet (Mediterranean Diet Adherence Screener [MEDAS] 
and Australian Recommended Food Score [ARFS]), cognitive engagement (BrainHQ-derived 
statistics) and physical activity interventions (physical activity calendars). Outcomes are 
measured at baseline, immediately post-intervention and at 3- and 6-month follow-up by 
researchers blind to group allocation.
Discussion: If successful and feasible, secondary prevention lifestyle interventions could 
provide a targeted, cost-effective way to reduce the number of people with cognitive decline 
going on to develop Alzheimer’s disease (AD) and other dementias.
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Introduction
The number of people with dementia is projected to rise to 
almost 75 million worldwide by 2030, and in the absence 
of a cure, there is an urgent need for strategies to reduce the 
number of people developing dementia.1 It has been estimated 
that up to half of all Alzheimer’s disease (AD) cases world-
wide may be attributed to seven modifiable risk factors, the 
majority of which reflect cardiovascular risks such as physical 
inactivity, hypertension, obesity, and diabetes.2
Primary prevention of dementia aims to reduce risk fac-
tors by focusing on improving the lifestyle of middle-aged 
people prior to or in the very earliest stages of the neuropatho-
logical changes which characterize AD and other types of 
dementia.3 An alternative strategy is secondary prevention, 
which aims to minimize any further damage or slow progres-
sion once symptoms of a disease begin to emerge. In the case 
of dementia, it is thought that the very earliest symptoms 
of disease are characterized by subjective cognitive decline 
(SCD) and later by mild cognitive impairment (MCI).3 SCD 
is a condition in which people report cognitive deficits in 
day-to-day life, but these are not detectable with cognitive 
testing.4 The cognitive deficits of people with MCI are detect-
able with cognitive testing, but do not reach the threshold 
to meet the criteria for dementia.5 Both SCD and MCI are 
associated with increased risk of progressing to dementia,5,6 
and the earliest stages of brain pathology found in dementia 
are also present in these conditions.7–10
Although dementia is not considered to be a reversible 
condition, there are some indications that in these prodromal 
stages the brain may still retain sufficient neuroplasticity that 
the trajectory of the disease may be modifiable. For instance, in 
individuals with MCI, conversion rates to AD are 7% at 1 year, 
24% at 3 years and 59% at 6 years.11,12 Annually, approxi-
mately 25% of those with MCI revert back to normal cogni-
tive status.13 There are differing explanations for this pattern 
of changes in cognitive status such as differing definitions 
for MCI, differences in testing procedures and test and retest 
effects that do not adequately represent these participants’ 
true level of cognitive function. One explanation that cannot 
be discounted is that these low annual conversion rates and a 
high percentage of people reverting back to cognitively normal 
status suggest that this period may represent a “window of 
opportunity” for interventions to modify the disease course.
Three factors that have been identified by systematic 
reviews as having the potential to decrease lifestyle risk 
of dementia are diet, cognitive engagement, and physical 
activity.14,15
One dietary pattern that has shown promise in recent 
research is the Mediterranean diet (MeDi). The MeDi is a 
dietary pattern which is predominantly plant-based, with a 
high intake of vegetables, fruits, nuts and legumes, moder-
ately high intake of fish, low intake of red meat, and includes 
extra virgin olive oil as the main source of fat.16 The MeDi 
has been shown to decrease dementia risk indirectly through 
altering cardiovascular risk factors,17 as well as directly 
through lower levels of neuropathology such as amyloid 
plaques,18 brain atrophy,19 and structural connectivity.20
One of the most compelling studies in the area of cog-
nitive engagement is the Advanced Cognitive Training in 
Vital Elderly (ACTIVE) trial.21 The ACTIVE trial was a 
computerized cognitive training randomized controlled 
trial (RCT), comparing memory, reasoning, and speed of 
processing training conditions to a control condition. The 
speed of processing training group showed higher cognition 
and lower incident dementia at 10 years post-intervention, 
relative to the control group.21,22 Although the ACTIVE trial 
was conducted with a cognitively normal sample over the 
age of 65 years, these effects have yet to be replicated in a 
group with cognitive decline, such as SCD or MCI.
Similar to diet, physical activity is both indirectly and 
directly related to dementia risk. Physical activity has repeat-
edly been shown to be protective against cardiovascular risk 
factors for dementia23 and to reduce AD risk directly through 
a host of neuronal mechanisms, including downregulating 
pathways that lead to amyloid and tau production.24 In a 
review of modifiable risk factors, physical inactivity has 
the highest attributable risk of the seven dementia risk 
factors identified (18% of all dementia cases in Australia).25 
Although the bulk of evidence for these factors comes from 
primary prevention studies (eg, with middle-aged adults), 
systematic reviews have highlighted the need to explore such 
approaches as secondary prevention interventions in people 
experiencing the earliest stages of cognitive decline.26–28
Some early studies in the area of secondary prevention 
have shown encouraging results. A 12-week, single-arm 
intervention for community-dwelling people with MCI 
(n=127, average age 70.7 years) involving MeDi, omega-3 
supplements, physical activity, cognitive stimulation, 
neurofeedback, and meditation achieved positive results.29 
At the final follow-up, 84% of the participants showed sta-
tistically significant improvements in cognition and 53% of 
a subsample (n=17) that underwent neuroimaging showed 
hippocampal growth. Limitations of this study were that there 
was no control group and participants were not randomized, 
making it difficult to determine whether the effects were due 
to the intervention, and the low number of participants in the 
neuroimaging subsample means that these changes may not 
be representative of the whole sample. The study concluded 
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that further multidomain RCTs should be conducted in par-
ticipants experiencing cognitive decline. One multidomain 
RCT was conducted in community-dwelling frail and prefrail 
participants over the age of 65 years, which compared inter-
ventions for physical activity, cognitive activity, nutrition, 
and a combination of the three interventions against a control 
group.30 Over 12 months, improvements in different domains 
of cognition were seen with all groups except the physical 
activity intervention group, in comparison to declines seen 
in the control group. As one of the limitations, the study 
noted that as physical frailty was the primary target of the 
intervention, only 7% of the sample had a Mini Mental State 
Examination (MMSE) score less than 26 and the study may 
have been underpowered to detect all cognitive effects. The 
study recommended that further multidomain RCTs should 
be trialed in participants with greater levels of cognitive 
impairment as greater benefits may be possible with this 
population.
Although preliminary studies on secondary prevention do 
report positive outcomes, there is a need for more rigorous, 
multidomain studies such as RCTs, designed specifically 
to look at relevant outcomes such as cognition and lifestyle 
risk factors.
Objectives
The Body, Brain, Life (BBL) interventions are a suite of mul-
tidomain, primary dementia risk reduction interventions.31–33 
The original intervention included educational modules only 
and more recently face-to-face physical activity and dietary 
components have been added.32 The present study, Body, 
Brain, Life for Cognitive Decline (BBL-CD), draws from the 
earlier interventions but introduces some new components 
and adaptations so that it is suitable for participants with 
cognitive impairment. This study evaluates the feasibility 
and efficacy of adapting this program for a cognitively 
impaired population.
The specific aims of the study are to
1. evaluate the efficacy of BBL-CD in the prevention of 
further cognitive decline;
2. evaluate the efficacy of BBL-CD to reduce overall life-
style risk of AD and other dementias and
3. evaluate the feasibility of BBL-CD through tracking 
intervention adherence.
Methods
Study design
The study is an 8-week, two-arm, parallel group RCT. The 
intervention focuses on the following three domains of 
lifestyle: diet, cognitive engagement, and physical activity. 
The active control group will undertake four online educa-
tional modules and the intervention group will undertake the 
same online modules complemented by practical and face-
to-face sessions with interventionists. The study is expected 
to complete data collection in late 2018. This study is reg-
istered with the Australian and New Zealand Clinical Trials 
Registry (ACTRN12617000792325) and ethical approval for 
conducting this study was granted by the Australian National 
University Human Research Ethics Committee (Protocol: 
2016/360). The study has been planned and conducted in 
accordance with the revised Declaration of Helsinki,34 and all 
participants provided written informed consent to participate 
in this study. This protocol was written to conform with the 
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) checklist.35
Participants
Participants are community-dwelling individuals with MCI 
or SCD recruited through advertisements in community 
newsletters, local print media, and radio. The inclusion cri-
teria are as follows: living in the Australian Capital Territory 
or Queanbeyan, New South Wales; aged 65 years or over; 
owning a computer with Internet access; having sufficient 
English language skills; being prepared to make lifestyle 
changes to improve health; and having a medical diagnosis 
of MCI or meeting the Jessen criteria4 for SCD (clinically 
normal on objective assessment, self/informant-reported 
cognitive decline, decline not better accounted for by major 
medical and neurological or psychiatric diagnosis). The 
criteria for MCI are met if the participant has previously 
received a diagnosis of MCI from a suitably qualified medical 
professional such as a neuropsychologist or geriatrician (no 
exact criteria for MCI diagnosis are specified). The criteria 
for SCD are met if the participant expresses the view that 
they have experienced a decline in any domains of cognitive 
function in the past 5 years.
Exclusion criteria are as follows: currently participating 
in any lifestyle change interventions; have a diagnosis of 
AD or another form of dementia and have major psychiatric, 
neurological, or physical problems which would prevent 
them from taking part in a lifestyle change program.
All inclusion and exclusion criteria are assessed via 
an initial phone call to the research team when potential 
participants express interest in participating in the study. 
Participants meeting the criteria are sent an information sheet 
about the study and a consent form to sign and return.
If at any of the testing points cognitive testing is indicative 
of potential AD (The Alzheimer’s Disease Assessment Scale-
Cognitive Subscale [ADAS-Cog] .12), participants are 
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
4.
17
3.
67
.8
2 
on
 1
9-
De
c-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2400
McMaster et al
referred to their general practitioner (GP) for cognitive testing. 
If found to have probable AD, the participant is withdrawn 
and no further data are collected; these participants are still 
allowed to continue participating in the practical components 
of the intervention, if they choose to (ie, participants will not 
be penalized or disadvantaged by a dementia diagnosis).
Randomization and stratification
After completing baseline data collection, participants are 
randomized in a 1:1 ratio, within strata defined by gender, 
baseline ADAS-Cog-Plus (above or below the median 
value of 7.0) and baseline ANU-ADRI (above or below the 
median value of 10.0), to intervention or control groups in 
permuted blocks of eight. The randomization sequence is 
generated from www.sealedenvelope.com by an independent 
researcher (RB).
Interventions
Active control
The active control group undertakes an 8-week, four-module, 
online educational course on dementia risk reduction and 
effective goal setting. The four modules are as follows:
1. Dementia literacy and lifestyle risk for AD (week 1): this 
module describes SCD, MCI, AD, and dementia, modifi-
able and non-modifiable risk factors and effective goal 
setting and rewards.
2. Diet (week 2): the diet module explains the importance of 
a healthy diet in maintaining a healthy brain. It explains 
the general principles of the MeDi and the scientific 
evidence that supports MeDi as a diet associated with 
lower levels of chronic disease and dementia.
3. Cognitive engagement (week 4): this module reviews the 
evidence for a cognitively engaged lifestyle being related 
to lower levels of dementia, different forms of cognitive 
engagement and how to increase cognitive engagement 
in everyday life.
4. Physical activity (week 6): this module discusses the 
evidence for an adequate level of physical activity in 
risk reduction of chronic disease and dementia. It also 
covers the importance of engaging in a combination 
of aerobic, strength, balance, and flexibility exercises 
and the Australian Department of Health’s Physical 
Activity and Sedentary Behaviour Guidelines for 
people $65 years.36
The modules are interactive, including some questions 
to check participants’ understanding of the content, and give 
the opportunity to provide information about aspects of their 
lifestyle and ways in which they might be able to modify 
their behavior. Each module provides examples of how to 
set specific, measurable, achievable, relevant, and timed 
(SMART) goals for the particular domain. Each module takes 
approximately 1–2 hours to complete and can be completed 
across multiple sittings, if desired.
Intervention
The intervention group receives the same educational 
modules as the active control group, but each module is 
complemented by practical components to assist with the 
implementation of changes into the lifestyle in a sustainable 
way. The practical components are as follows:
1. Diet: to reinforce the content of the diet module, the par-
ticipants have three face-to-face sessions with a dietitian, 
including an initial 1-hour session (week 3) and two further 
30-minute follow-up sessions (weeks 10 and 21). In these 
sessions, the dietitian reviews the participant’s previous 
diet assessment results, discusses any barriers to adherence 
they are experiencing and ways in which the participant 
could achieve greater adherence to the MeDi. The MeDi 
intervention is adapted from the study by Estruch et al.37 
Recommendations are as follows: 1) $5 servings of veg-
etables/day, including two servings of raw vegetables; 2) 
$3 servings of fruit/day; 3) $3 serves of fish or seafood/
week, including one serving of fatty fish; 4) $3 serv-
ings of legumes/week; 5) $3 servings of nuts/week; 6) 
preferentially consume white meat, instead of red meat; 
7) ,1 serving of red meat/day; 8) using olive oil as the 
main oil for cooking and dressing; 9) $4 servings of olive 
oil/day; 10) ,1 serving of butter, margarine, or cream/
day; 11) $7 servings of wine/week; 12) $2 servings of 
sofrito sauce/week (tomato, garlic, onion, and olive oil); 
13) ,1 serving of sweet or carbonated beverages/day; and 
14) ,3 servings of commercial sweets or pastries/week.
2. Cognitive engagement: to enable the participants to live 
a more cognitively engaged lifestyle, they are provided 
with a BrainHQ38 account (week 5) and asked to partici-
pate in two executive functions and two memory tasks 
for 30 minutes each (total 2 hours) per week. The four 
tasks are as follows: Double Decision (divided and selec-
tive attention, speed of processing, dual task, and useful 
field of view); Freeze Frame (visual phasic and tonic 
attention, inhibitory control and motor response inhibi-
tion); Syllable Stacks (auditory working memory); and 
Memory Grid (auditory spatial memory). The exercises 
are psychophysically adaptive and the parameters within 
each stimulus set are adjusted for an individual participant 
to maintain ~80% criterion accuracy by increasing or 
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decreasing task difficulty systematically with correct/
incorrect responses.
3. Physical activity: participants attend an initial 45-minute 
session (week 7) and two 30-minute follow-up sessions 
with an exercise physiologist (weeks 10 and 21). Based 
on the participant’s medical conditions, current level 
of exercise and physical activity preferences, a weekly 
exercise regime is developed with the eventual aim to 
increase physical activity level to 150 minutes of moderate 
exercise per week. If participants are already undertaking 
this level of exercise or greater, the goal is maintenance 
and combining different forms of exercises (eg, aero-
bic, strength, balance, and flexibility exercises). In the 
follow-up sessions, the exercise physiologist discusses 
progress, any barriers that the participant is experiencing 
and any modifications to the exercise regime, and (if suit-
able) increases toward 150 minutes total exercise duration. 
To be involved in these sessions, participants must have 
a medical clearance form signed by a GP, detailing any 
medical conditions or medications which may impact the 
participant’s ability to undertake exercise and approving 
the participant to undertake moderate physical exercise.
A week-by-week summary of the intervention is shown 
in Figure 1.
Modifications made to previous BBL 
interventions
The BBL intervention has been modified each time it has been 
conducted, based on participant feedback on the previous 
version.31–33 Further modifications were made for this study 
to increase the suitability for an older population experiencing 
cognitive decline. The overall size and amount of informa-
tion that participants are required to learn and remember in 
the online modules were decreased based on feedback from 
middle-aged participants that there was too much information 
to read and remember. Previous versions of BBL contained 
seven or eight informational modules on different dementia 
risk factors, followed by 4 weeks of revision. To enable a 
population experiencing cognitive deficits to effectively learn 
and modify their behavior without being overwhelmed, the 
content was reduced to three risk factors that could be most 
easily targeted to bring about effective risk reductions. Previ-
ous BBL studies involved one module on a new risk factor 
per week for the first 8 weeks. In BBL-CD, after a module 
on a risk factor is introduced, a week without a module is 
allotted for participants to implement these changes into their 
lifestyle. In BBL-CD, in week 8 at the conclusion of all the 
modules the participants have a week for revision and are 
sent a one-page summary of each module to convey the key 
messages of the intervention. Each module summary also 
provides an example of a SMART goal for that specific 
risk factor, so that participants can continue to modify their 
behavior beyond the initial 8-week intervention period. 
Specific modifications to the modules included the follow-
ing: the diet module and practical intervention were modified 
from the previous BBL focusing on a healthy balanced diet 
to the MeDi in consultation with study dietitians; the brain 
training is a novel inclusion due to a change in the participant 
group to one experiencing cognitive decline; and the physical 
activity program is now focused on moderate physical 
activity, rather than a structured walking program based on 
feedback from participants who felt that the walking program 
was too restrictive. These modified modules and practical 
components were piloted with a small group of individuals 
(n=7) who volunteered to be participants but failed to meet a 
small number of the selection criteria (eg, less than 65 years 
of age, medical condition preventing dietary modification, 
etc). Feedback on each module and practical component 
was collected, and although overall feedback was positive, 
some modifications were implemented, eg, module wording 
changes and materials used during practical components.
Due to the high attrition rate in longitudinal intervention 
studies, several strategies to decrease attrition are being 
implemented. To make participants feel included and valued 
in the scientific process, newsletters are periodically sent 
about the progress of the study; participants are informed 
about any publications/conference presentations from the 
research; and participants are thanked after attending data 
collection and intervention sessions. The intervention group 
is termed the “Lifestyle Intervention Group” and the control 
group is termed the “Online Education Group”, such that 
participants in the control group do not feel they are receiving 
an intervention that is unlikely to have any effect.
outcome measures
Primary outcome measures
Cognition
Cognition is measured by the ADAS-Cog-Plus,39 which con-
tains the standard ADAS-Cog items (word recall, naming 
objects and fingers, following commands, constructional 
praxis, ideational praxis, orientation, word recognition, 
language production, language comprehension, and word 
finding difficulty)40 with additional measures for executive 
function (trail making task,41 symbol digit modalities test,42 
category fluency task,)43 and instrumental activities of daily 
living (Pfeffer Functional Activities Questionnaire items 
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1, 2, 4, 7 and 9).44 The inclusion of executive function and 
instrumental activities of daily living items is designed to 
maximize sensitivity to early-stage deficits as seen in SCD 
and MCI. The ADAS-Cog is scored from 0 to 70, with higher 
scores indicating greater levels of cognitive impairment. 
ADAS-Cog has good reliability (Cronbach’s α=0.83, test–
retest=0.93)45 and has been shown to discriminate between 
individuals with normal cognition, MCI and AD.40 The 
inclusion of a full battery of cognitive measures is a new 
inclusion for the BBL studies, given a population experienc-
ing cognitive decline.
lifestyle risk of Ad
Lifestyle risk factors for AD are measured by the Australian 
National University – Alzheimer’s Disease Risk Index 
(ANU-ADRI).46 The ANU-ADRI covers 11 AD risk factors 
(eg, age, education and smoking) and four lifestyle factors 
that are protective against AD (eg, physical activity, fish 
intake, and cognitive activity). The ANU-ADRI applies an 
AD risk score for the level of each risk or protective factor, 
based on ORs derived from systematic reviews.46 The ANU-
ADRI yields a score ranging from -14 (highly protective 
lifestyle) to 73 (high-risk lifestyle). The ANU-ADRI has 
Figure 1 timing of intervention components and testing periods.
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been validated against three large, international longitudi-
nal cohort studies and was shown to be a valid predictor of 
development of AD.47
Secondary outcome measures
Motivation
Motivation to change lifestyle is being assessed by 
the Motivation to Change Lifestyle and Health Behaviour 
for Dementia Risk Reduction (MCLHB-DRR).48 This is a 
27-item scale, which was developed based on the principles 
of the Health Belief Model. It was developed and validated 
specifically to look at motivation to change lifestyle in health 
and dementia lifestyle interventions.
Health-related quality of life
The 36-item Short Form Health Survey (SF-36)49 is being 
used to assess general health-related quality of life. The 
SF-36 has 36-items which form an eight-scale profile of 
health-related quality of life which can be summarized 
into a physical component summary (PCS) and mental 
component summary (MCS). An overall score of 0–100 
can be calculated from the mean values of the eight scales. 
Higher scores indicate better health-related quality of life. 
The SF-36 is commonly used in health research, especially 
in the evaluation of interventions, as it is easily converted 
to quality of life years (QALYs), which gives a quantitative 
measure of the benefit of an intervention and can be used in 
a cost–benefit analysis.50
Anthropometric measures
Height, weight, waist, and hip circumference are collected. 
Height to the nearest millimeter is measured using a stadi-
ometer (Seca, Hamburg, Germany), and weight to the near-
est 0.1 kg is measured with digital scales (Propert, Sydney, 
NSW, Australia).51 Body mass index is calculated as weight 
(kg) divided by height squared (m2). Waist circumference 
is measured to the nearest centimeter midway between the 
lowest rib margin and the iliac crest.51 Hip circumference is 
measured to the nearest centimeter at the point yielding the 
maximum circumference over the buttocks.51
Feasibility and adherence measures
The feasibility of the lifestyle intervention for this partici-
pant group is measured through adherence to diet, cognitive 
engagement, and physical activity. Additional qualitative 
interviews with a subsample of participants will be under-
taken at the conclusion of the study to investigate other 
factors affecting feasibility and adherence to interventions 
such as this.
dietary assessment
Dietary adherence to the MeDi is assessed using a vali-
dated 14-point Mediterranean Diet Adherence Screener 
(MEDAS).52 A score of 0 or 1 is assigned to each item, with 
a maximum score of 14 indicating greatest adherence to 
the MeDi. The MEDAS has good convergent validity with 
a 137-item MeDi food frequency questionnaire and shows 
significant associations with health indices such as fasting 
glucose, total:high-density lipoprotein (HDL) cholesterol 
ratio, triglycerides and coronary artery disease risk.52
Dietary quality is assessed with a food-based diet quality 
index, the Australian Recommended Food Score (ARFS).53 
The ARFS is aligned with Australian Dietary Guidelines54 
and the Australian Guide to Healthy Eating55 recommenda-
tions. The ARFS total ranges from 0 to 73 and includes eight 
subscales: vegetables (0–21), fruit (0–12), protein (0–7), veg-
etarian protein alternatives (0–6), grains (0–13), dairy (0–11), 
water (0–1), and sauces and condiments (0–2). Higher scores 
indicate greater compliance with the Australian Dietary 
Guidelines and therefore better diet quality. The ARFS has 
demonstrated good validity and reproducibility.53
Cognitive engagement
Duration of engagement with cognitive training and levels 
completed are tracked automatically via the BrainHQ website 
for the intervention group.
Physical activity
Participants track their daily physical activity on a paper-
based physical activity calendar. The activity, intensity (on 
a 20-point scale),56 and duration of the physical activity are 
recorded. Participants are asked to start completing this 
measure from the day of baseline testing onward and return 
these to the research team by electronic scan and email or 
by post at the end of every month.
data collection
There are four primary data collection points in the study as 
follows: baseline (week 0); immediate post-intervention test-
ing (week 9); 3-month testing (week 20); and 6-month testing 
(week 32). Research staff collecting data are blind to group 
allocation. Not all outcome measures are administered at each 
time point, and a summary of this is presented in Table 1.
Statistical methods
Sample size calculation
The required sample size was determined to enable detec-
tion of a difference between groups at 6 months of 0.70 SDs 
for the primary outcomes. This equates to approximately 
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4.2 units for the ADAS-Cog-Plus and 4.0 units on the ANU-
ADRI, both of which are clinically significant magnitudes. 
This requires a minimum of 72 participants (36 participants 
per arm) at the final follow-up period. Accounting for a 
potential attrition rate of 10% over four testing periods 
(60% remaining) yields a target sample size at baseline of 
60 participants per group (120 in total).
Planned analyses
Linear mixed modeling to compare outcomes between inter-
vention and control groups at each follow-up time, adjusted 
for baseline values of the outcome, will be conducted using 
complete cases as the primary analysis and full intention-
to-treat analysis using multiple imputation to account for 
missing data as sensitivity analysis.
Discussion
There is a clear need for dementia prevention and risk reduc-
tion studies, given the anticipated rise in the number of people 
with dementia in the coming years.1 Several authors have 
argued that secondary prevention (older populations show-
ing some symptoms of cognitive decline) is an avenue that 
warrants further exploration.26–28 Drawing on epidemiological 
findings and previous trials and applying this to an older, 
high-risk group is the strategy that has been adopted for this 
study. Secondary prevention, if feasible and effective, pro-
vides a targeted approach to reducing the number of people 
developing dementia. Such intervention programs could be 
implemented through primary care providers who identify 
individuals in the high-risk SCD/MCI groups. Interventions 
could be run as collaborations between medical and allied 
health professionals and could be tailored to individuals’ spe-
cific needs based on their risk factor profile. Targeting a small 
number of people at very high risk of developing dementia 
would likely prove to be more cost-effective than targeting 
a larger number of people at lower risk.
The first step to showing the value of secondary preven-
tion is to conduct randomized controlled studies to demon-
strate feasibility and positive effects, such as reductions in 
risk factors or improvements in cognition in the SCD/MCI 
group. As a smaller, proof of concept study this research 
focuses on three of the most important risk factors: diet, 
cognitive engagement and physical exercise. This study 
aims to evaluate the efficacy of BBL-CD to prevent further 
cognitive decline and dementia risk profile and to evalu-
ate the feasibility of the intervention for this participant 
group. These findings would provide proof of concept for 
a larger, longer secondary prevention trial with this group 
in the future.
Strengths and limitations
A major strength of this project is that all the components of 
the intervention have previously been used in separate suc-
cessful interventions,21,31,32,37 but not with a group experienc-
ing cognitive decline. The efficacy and feasibility of dementia 
risk reduction interventions in this group have been identified 
as a major knowledge gap by systematic reviews,26–28 and the 
use of multidomain interventions to combat multiple risk 
factors simultaneously is considered to be the “gold standard” 
for risk reduction and prevention interventions.28
The greatest limitation of this research is the short 
follow-up time. Systematic reviews of RCTs in dementia 
Table 1 Summary of outcomes measured at data collection points
Baseline  
(week 0)
Immediate post- 
intervention (week 9)
3-month follow-up  
(week 20)
6-month follow-up  
(week 32)
Primary outcomes
Cognition   
lifestyle risk    
Secondary outcomes
Motivation    
Health    
Anthropometry   
Feasibility outcomes
Mediterranean diet    
dietary quality   
Cognitive engagement Collected daily from week 5 onward for the intervention group
Physical activity Collected daily from baseline (week 0) onward
Note: data collection at baseline, 3-month and 6-month follow-up is conducted face-to-face, and immediate post-intervention assessments are online questionnaires.
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risk reduction interventions recommend follow-up times 
of a year or longer.27 Due to the paucity of research in the 
area of secondary prevention, it is important to first estab-
lish the feasibility of an adaptation of the BBL intervention 
to the SCD/MCI group and test the hypotheses that these 
individuals do appear to retain sufficient neuroplasticity to 
warrant a larger and longer trial.
Data sharing statement
Deidentified individual data sets are available indefinitely 
upon request to the authors following publication of the 
results of the study.
Acknowledgments
We thank Dr Richard Burns for his advice and assistance with 
the randomization of the sample. MM’s PhD Scholarship is 
supported by Dementia Australia Research Foundation, the 
Australian National University and Dementia Collaborative 
Research Centre. Additional research funding is provided by 
the NHMRC Centre for Research Excellence in Cognitive 
Health, the Australian National University; Neuroscience 
Research Australia, University of New South Wales; the 
2017 Royal Commonwealth Society Phyllis Montgomery 
Award; NHMRC Fellowship Funds (KA: APP1102694); 
and the Dementia Collaborative Research Centre (funds for 
precursor study). SK and LC are funded by the NHMRC 
Centre for Research Excellence in Cognitive Health. None of 
the funding bodies played any part in the study conception, 
design, or conduct of the study.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Alzheimer’s Disease International. World Alzheimer’s Report 2015. 
The Global Impact of Dementia. An Analysis of Prevalence, Incidence, 
Cost and Trends. 2015.
2. Barnes DE, Yaffe K. The projected effect of risk factor reduction on 
Alzheimer’s disease prevalence. Lancet Neurol. 2011;10(9):819–828.
3. Fratiglioni L, Winblad B, von Strauss E. Prevention of Alzheimer’s 
disease and dementia. Major findings from the Kungsholmen Project. 
Physiol Behav. 2007;92(1–2):98–104.
4. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework 
for research on subjective cognitive decline in preclinical Alzheimer’s 
disease. Alzheimers Dement. 2014;10(6):844–852.
5. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern 
Med. 2004;256(3):183–194.
6. Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk 
of dementia and mild cognitive impairment in older people with subjec-
tive memory complaints: meta-analysis. Acta Psychiatr Scand. 2014; 
130(6):439–451.
7. Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive com-
plaints and amyloid burden in cognitively normal older individuals. 
Neuropsychologia. 2012;50(12):2880–2886.
 8. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging 
and memory in non-demented individuals: evidence for preclinical 
Alzheimer’s disease. Brain. 2007;130(Pt 11):2837–2844.
 9. Shi F, Liu B, Zhou Y, Yu C, Jiang T. Hippocampal volume and 
asymmetry in mild cognitive impairment and Alzheimer’s disease: meta-
analyses of MRI studies. Hippocampus. 2009;19(11):1055–1064.
 10. Perrotin A, de Flores R, Lamberton F, et al. Hippocampal subfield 
volumetry and 3D surface mapping in subjective cognitive decline. 
J Alzheimers Dis. 2015;48(s1):S141–S150.
 11. Bradfield NI, Ellis KA, Savage G, et al. Baseline amnestic severity 
predicts progression from amnestic mild cognitive impairment to 
Alzheimer disease dementia at 3 years. Alzheimer Dis Assoc Disord. 
2018;32(3):190–196.
 12. Wallin A, Nordlund A, Jonsson M, et al. The Gothenburg MCI study: 
design and distribution of Alzheimer’s disease and subcortical vascular 
disease diagnoses from baseline to 6-year follow-up. J Cereb Blood 
Flow Metab. 2016;36(1):114–131.
 13. Malek-Ahmadi M. Reversion from mild cognitive impairment to 
normal cognition: a meta-analysis. Alzheimer Dis Assoc Disord. 2016; 
30(4):324–330.
 14. Xu W, Tan L, Wang HF, et al. Meta-analysis of modifiable risk factors 
for Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2015;86(12): 
1299–1306.
 15. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. 
Summary of the evidence on modifiable risk factors for cognitive decline 
and dementia: a population-based perspective. Alzheimers Dement. 
2015;11(6):718–726.
 16. Davis C, Bryan J, Hodgson J, Murphy K. Definition of the Mediter-
ranean diet; a literature review. Nutrients. 2015;7(11):9139–9153.
 17. Salas-Salvadó J, Becerra-Tomás N, García-Gavilán JF, Bulló M, 
Barrubés L. Mediterranean diet and cardiovascular disease prevention: 
what do we know? Prog Cardiovasc Dis. 2018;61(1):62–67.
 18. Berti V, Walters M, Sterling J, et al. Mediterranean diet and 3-year 
Alzheimer brain biomarker changes in middle-aged adults. Neurology. 
2018;90(20):e1789–e1798.
 19. Luciano M, Corley J, Cox SR, et al. Mediterranean-type diet and brain 
structural change from 73 to 76 years in a Scottish cohort. Neurology. 
2017;88(5):449–455.
 20. Pelletier A, Barul C, Féart C, et al. Mediterranean diet and preserved 
brain structural connectivity in older subjects. Alzheimers Dement. 
2015;11(9):1023–1031.
 21. Rebok GW, Ball K, Guey LT. Ten-year effects of the ACTIVE cogni-
tive training trial on cognition and everyday functioning in older adults. 
J Am Geriatr Soc. 2014;62(1):16.
 22. Edwards JD, Xu H, Clark D, Ross LA, Unverzagt FW. The ACTIVE 
study: what we have learned and what is next? Cognitive training 
reduces incident dementia across ten years. Alzheimer’s Dementia. 2016; 
12(7):P212.
 23. Lanier JB, Bury DC, Richardson SW. Diet and Physical activity for 
cardiovascular disease prevention. Am Fam Physician. 2016;93(11): 
919–924.
 24. Loprinzi PD, Frith E, Ponce P. Memorcise and Alzheimer’s disease. 
Phys Sportsmed. 2018;46(2):145–154.
 25. Ashby-Mitchell K, Burns R, Shaw J, Anstey KJ. Proportion of dementia 
in Australia explained by common modifiable risk factors. Alzheimers 
Res Ther. 2017;9(1):11.
 26. Horr T, Messinger-Rapport B, Pillai JA. Systematic review of strengths 
and limitations of randomized controlled trials for non-pharmacological 
interventions in mild cognitive impairment: focus on Alzheimer’s 
disease. J Nutr Health Aging. 2015;19(2):141–153.
 27. Smart CM, Karr JE, Areshenkoff CN, et al. Non-pharmacologic inter-
ventions for older adults with subjective cognitive decline: systematic 
review, meta-analysis, and preliminary recommendations. Neuropsychol 
Rev. 2017;27(3):245–257.
 28. Williams JW, Plassman BL, Burke J, Holsinger T, Benjamin S. Pre-
vention Alzheimer’s Disease and Cognitive Decline. Rockville, MD: 
Agency for Healthcare Research and Quality (US); 2010.
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
4.
17
3.
67
.8
2 
on
 1
9-
De
c-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal
Clinical Interventions in Aging is an international, peer-reviewed journal 
focusing on evidence-based reports on the value or lack thereof of treatments 
intended to prevent or delay the onset of maladaptive correlates of aging 
in human beings. This journal is indexed on PubMed Central, MedLine, 
CAS, Scopus and the Elsevier Bibliographic databases. The manuscript 
management system is completely online and includes a very quick and fair 
peer-review system, which is all easy to use. Visit http://www.dovepress.
com/testimonials.php to read real quotes from published authors.
Clinical Interventions in Aging 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
2406
McMaster et al
 29. Fotuhi M, Lubinski B, Trullinger M, et al. A Personalized 12-week 
“Brain Fitness Program” for improving cognitive function and increas-
ing the volume of hippocampus in elderly with mild cognitive impair-
ment. J Prev Alzheimers Dis. 2016;3(3):133–137.
 30. Ng TP, Ling A, Feng L, et al. Cognitive effects of multi-domain inter-
ventions among pre-frail and frail community-living older persons: 
randomized controlled trial. J Gerontol Series A. 2017.
 31. Anstey KJ, Bahar-Fuchs A, Herath P, et al. Body brain life: a random-
ized controlled trial of an online dementia risk reduction intervention in 
middle-aged adults at risk of Alzheimer’s disease. Alzheimers Dement. 
2015;1(1):72–80.
 32. Kim S, Mcmaster M, Torres S, et al. Protocol for a pragmatic ran-
domised controlled trial of Body Brain Life-General Practice and a 
Lifestyle Modification Programme to decrease dementia risk exposure 
in a primary care setting. BMJ Open. 2018;8(3):e019329.
 33. Anstey KJ, Kim S [homepage on the Internet]. The Body, Brain, Life-
Fit (BBL-FIT) Program – A Pilot Study to Evaluate the Feasibility 
of the BBL-FIT Online Lifestyle Program in Middle-Aged Adults at 
Risk of Dementia (ACTRN12615000822583). Australian and New 
Zealand Clinical Trial Registry. Available from: https://www.anzctr.
org.au/Trial/Registration/TrialReview.aspx?id=368897;2015. Accessed 
October 24, 2018.
 34. World Medical Association. World Medical Association Declaration 
of Helsinki: ethical principles for medical research involving human 
subjects. JAMA. 2013;310(20):2191.
 35. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: 
defining standard protocol items for clinical trials. Ann Intern Med. 
2013;158(3):200–207.
 36. Australian Department of Health [homepage on the Internet]. Physical 
Activity and Sendentary Behaviour Guidelines. Physical Activity and 
Sendentary Behaviour Guidelines. Available from: http://www.health.
gov.au/internet/main/publishing.nsf/content/health-pubhlth-strateg-
phys-act-guidelines#chba. Accessed 1/5/2018.
 37. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of car-
diovascular disease with a Mediterranean diet. N Engl J Med. 2013; 
368(14):1279–1290.
 38. Posit Sceince [homepage on the Internet]. BrainHQ. Available from: 
http://www.brainhq.com. Accessed October 3, 2018.
 39. Skinner J, Carvalho JO, Potter GG, et al. The Alzheimer’s Disease 
Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion 
of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging 
Behav. 2012;6(4):489–501.
 40. Kueper JK, Speechley M, Montero-Odasso M. The Alzheimer’s Disease 
Assessment Scale-Cognitive Subscale (ADAS-Cog): modifications 
and responsiveness in pre-dementia populations. A narrative review. 
J Alzheimers Dis. 2018;63(2):423–444.
 41. Reitan RM. Trail Making Test: Manual for Administration and Scoring. 
Tucson, AZ: Reitan Neuropsychology Laboratory; 1992.
 42. Smith A. Symbol Digit Modalities Test. Los Angeles, CA: Western 
Psychological Services; 1982.
 43. Lucas JA, Ivnik RJ, Smith GE, et al. Mayo’s older Americans norma-
tive studies: category fluency norms. J Clin Exp Neuropsychol. 1998; 
20(2):194–200.
 44. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement 
of functional activities in older adults in the community. J Gerontol. 
1982;37(3):323–329.
 45. Cano SJ, Posner HB, Moline ML, et al. The ADAS-cog in Alzheimer’s 
disease clinical trials: psychometric evaluation of the sum and its parts. 
J Neurol Neurosurg Psychiatry. 2010;81(12):1363–1368.
 46. Anstey KJ, Cherbuin N, Herath PM. Development of a new method 
for assessing global risk of Alzheimer’s disease for use in population 
health approaches to prevention. Prev Sci. 2013;14(4):411–421.
 47. Anstey KJ, Cherbuin N, Herath PM, et al. A self-report risk index to 
predict occurrence of dementia in three independent cohorts of older 
adults: the ANU-ADRI. PLoS One. 2014;9(1):e86141.
 48. Kim S, Sargent-Cox K, Cherbuin N, Anstey KJ. Development of the 
motivation to change lifestyle and health behaviours for dementia risk 
reduction scale. Dement Geriatr Cogn Dis Extra. 2014;4(2):172–183.
 49. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey 
(SF-36). I. Conceptual framework and item selection. Med Care. 1992; 
30(6):473–483.
 50. Brazier J, Roberts J, Deverill M. The estimation of a preference-based mea-
sure of health from the SF-36. J Health Econ. 2002;21(2):271–292.
 51. Gibson RS. Principles of Nutritional Assessment. 2nd ed. New York: 
Oxford University Press; 2005.
 52. Schröder H, Fitó M, Estruch R, et al. A short screener is valid for 
assessing Mediterranean diet adherence among older Spanish men and 
women. J Nutr. 2011;141(6):1140–1145.
 53. Collins CE, Burrows TL, Rollo ME, et al. The comparative validity 
and reproducibility of a diet quality index for adults: the Australian 
Recommended Food Score. Nutrients. 2015;7(2):785–798.
 54. National Health and Medical Research Council. Australian Dietary 
Guidleines. Available from: https://www.nhmrc.gov.au/guidelines-
publications/n55. Accessed on 10 May 2018. 2013.
 55. National Health and Medical Research Council. Australian Guide 
to Healthy Eating. Canberra: National Health and Medical Research 
Council; 2003.
 56. Borg G. Borg’s Perceived Exertion and Pain Scales. Champaign, IL: 
Human kinetics; 1998.
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
4.
17
3.
67
.8
2 
on
 1
9-
De
c-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
